A new perspective in melanoma treatment: Melanocortin receptor 4 antagonist in association with B-Raf inhibitor Vemurafenib
Stefano Pioli, Paola Orlandi, Arianna Bandini, Alessandra Ottani, Eleonora Vandini, Guido Bocci, Daniela Giuliani · FENS Forum 2024
The melanocortin receptor subtype 4 (MC4R) is expressed in various human cells such as skin melanocytes, astrocytes, and neural progenitor cells1.Our aim is to evaluate the role of MCR4 as a novel target in melanoma therapy, using a selective antagonist ML00253764 (ML) alone and in combination with the B-Raf V600E inhibitor Vemurafenib.We employed the human melanoma B-Raf mutated A-2058 and WM 266-4 cell lines, while the CRISPR/Cas9 system was used to eliminate the MCR4 gene in the A-2058 cell line (MCR4 null).MC4R protein expression in melanoma cells was then tested though immunohistochemistr
ePoster · Neuroscience